To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Patients must have histologically or cytologically confirmed non-small cell lung cancer.
Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
ECOG PS 0-2
Adequate organ and bone marrow function.
History of previous radiotherapy.
The previous immune-related pneumonitis ≥ grade 2.
Local lesions require surgery.
History of another primary malignancy.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead sponsor